Abstract
In a clinical trial, performed according to new criteria of the AMG (Arzneimittelgesetz) 1976, a new choleretic monosubstance 3-n-butoxy-1-phenoxy-2-propanol (code number: K 10.033, H 33, febuprol, Valbil) has been tested. The clinical investigations conducted on 712 healthy volunteers and patients within a period of 4 years showed that Valbil is an effective and safe drug. Besides the choleretic properties, febuprol has some additional spasmolytic and lipid lowering effects.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
English Abstract
MeSH terms
-
1-Propanol / adverse effects
-
1-Propanol / metabolism
-
1-Propanol / therapeutic use
-
Animals
-
Cholagogues and Choleretics / adverse effects
-
Cholagogues and Choleretics / metabolism
-
Cholagogues and Choleretics / therapeutic use*
-
Cholecystitis / drug therapy
-
Dogs
-
Drug Interactions
-
Humans
-
Kinetics
-
Lipids / blood
-
Parasympatholytics
-
Phenyl Ethers
-
Propanols*
-
Rabbits
-
Rats
-
Risk
Substances
-
Cholagogues and Choleretics
-
Lipids
-
Parasympatholytics
-
Phenyl Ethers
-
Propanols
-
1-Propanol
-
febuprol